李建军

李建军，男，主任医师，山西省晋城市人，中共党员，毕业于首都医科大学，介入放射学医学博士，主任医师。师从翟仁友教授（原中华医学会放射学会介入学组副组长）、杨维竹教授（原福建省放射学会主任委员，福建省介入学组组长）郑加生教授（原中关村肿瘤微创治疗产业技术创新战略联盟理事长）、禇建国教授（北京健康促进会门静脉高压分会主任委员）。现为首都医科大学附属北京佑安医院肝病与肿瘤微创介入治疗中心副主任。 自2001年开始从事介入治疗，已做各种介入手术20000余台。可对原发性肝癌、肝转移癌、布加综合征、脾功能亢进、肝血管瘤、肺癌、肺转移癌、肾癌、膀胱癌、子宫肌瘤、支气管扩张大咯血、门静脉高压、肺栓塞、深静脉血栓、肾动脉狭窄；颈动脉狭窄等疾病行血管性介入治疗；并可对梗阻性黄疸、肝囊肿、肝脓肿、食管狭窄、气管狭窄、肠道狭窄、骨肿瘤等行非血管介入治疗。 发表文章 1. 李建军，杨维竹，江娜，等. 微导管用于肝动－门脉栓塞治疗肝癌. 福建医科大学学报，2004, 38(2): 207－208. 2. 李建军，杨维竹，江娜，等. 经导管选择性门静脉栓塞治疗肝癌的临床应用. 世界华人消化杂志，2004，12(10): 2291－2294. 3. 李建军，杨维竹，江娜，等. 经导管门静脉栓塞诱导肝叶代偿性增生的临床应用研究. 中华放射学杂志，2006，40(1):186－190. 4. Huang JY, Yang WZ, Li JJ, et al. Portal vein embolization induces compensatory hypertrophy of remnant liver. World J Gastroentrol, 2006, 12(3): 408－414. 5. 李建军，翟仁友，戴定可，等. 急性大面积肺栓塞的介入机械碎栓治疗. 介入放射学杂志，2006，15(6):336－338. 6. 李建军，翟仁友，戴定可，等. 支气管动脉栓塞术治疗咯血的临床疗效分析. 介入放射学杂志，2007,16(1):21-23. 7. 李建军，翟仁友，张东坡，等.多层螺旋CT灌注成像评价伊达拉奉防治肺栓塞缺血－再灌注损伤疗效的实验研究.中华放射学杂志，2008,42(10):1089-1094. 8. 李建军，翟仁友，戴定可，等.原发性肝癌合并梗阻性黄疸介入治疗近期疗效分析.中国介入放射学，2008,2(1):91-94. 9. 李建军，翟仁友，张东坡，等.犬肺栓塞缺血－再灌注损伤模型的实验研究.介入放射学杂志，2009,18(1):40-43. 10. 李建军，郑加生，崔雄伟，等. CT引导下肝肿瘤射频消融治疗的并发症分析. 介入放射学杂志，2009,18(5):406-409. 11. 郑加生，李建军，崔雄伟，等. 肝癌化疗栓塞术联合射频消融治疗疗效分析. 介入放射学杂志，2009, 18(5):342-345. 12. 李建军，郑加生，崔雄伟，等. 64排CT、DSA、C臂CT检出肝癌小病灶的对比. 中国介入影像与治疗学杂志，2011,8(3):236-239. 13. 李建军，郑加生，崔雄伟，等.CT引导肝肿瘤经皮射频消融术后胆道并发症防治. 介入放射学杂志，2011, 20(12):991-994. 14. 李建军，郑加生，崔雄伟，等.CT引导氩氦刀冷冻消融治疗骨转移癌的临床疗效初探. 当代医学，2012, 18(18):35-36. 15. 郑加生，李建军. 进修医师肝肿瘤射频消融治疗技术培训探讨.中国医学教育技术,2013,27(1):105-107. 16. Zheng JS, Li JJ, Cui XW, et al. Comparison of diagnostic sensitivety of C-arm CT,DSA and CT in detecting small HCC. Hepatogastroenterology, 2013, 60(126):1509-1512. 17. 李建军，郑加生，崔雄伟，等.C形臂碘油CT在肝癌肝动脉化疗栓塞术中的应用价值.中华介入放射学电子杂志,2013,1(2):110-113. 18. 李建军，郑加生. 进修医师肝癌血管介入治疗教学培训实践.中国医学教育技术,2014,28(6):663-665. 19. 李建军，郑加生，崔雄伟，等.CT引导下经皮微波消融治疗肺癌的临床疗效分析.中华介入放射学电子杂志,2014,2(1):35-37. 20. Li JJ, Zheng JS, Cui SC, Cui XW, Hu CX, Fang D, Ye LC. C-arm Lipiodol CT in transcatheter arterial chemoembolization for small hepatocellular carcinoma. World J Gastroenterol 2015; 21(10): 3035-3040. 21. 李建军，朱桐，杨晓珍，等. 肝上皮样血管内皮瘤肝动脉栓塞联合微波消融治疗效果初步分析(附4例报告).北京医学,2017,39(12):1209-1212. 22. 李建军，郑加生，崔石昌，等.肝细胞癌射频消融术后局部复发因素分析.北京医学,2018,40(7):697-699. 23. Wang Q, Ma L, Li J, et al. A novel scoring system for patients with recurrence of hepatocellular carcinoma after undergoing minimal invasive therapies. Cancer Management and Research, 2019,11:10641-10649. 24. Wang Q, Li J, Sun JP, Li K, Zhao Y, Zhang YH. Prognostic value of combined preoperative fibrinogen and platelet-lymphocyte ratio in patients with early recurrent hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi.2019,99(35):2781-2784. 25. 李建军，朱桐，杨晓珍，等. TIPS 联合TACE 序贯热消融治疗门静脉高压症合并肝细胞癌疗效分析. 中华介入放射学电子杂志,2021,9(3):252-257. 26. 江晴贵,李建军,郑晖,等.限制性扩张支架对肝硬化门静脉高压经颈静脉肝内门体分流患者预后的影响.中国介入影像与治疗学杂志,2021,18(4):193-197. 27. Tsauo J, Tie J, Xue H, Zhao JB, Li JJ, Fang ZT, Guo WH, Li X. Transjugular Intrahepatic Portosystemic Shunt Creation for the Prevention of Gastric Variceal Rebleeding in Patients with Hepatocellular Carcinoma: A Multicenter Retrospective Study. J Vasc Interv Radiol 2021, 32(7):963–969. 28. Wang Q, Liu B, Qiao W, Li J, Yuan C, Long J, Hu C, Zang C, Zheng J, Zhang Y. The Dynamic Changes of AFP From Baseline to Recurrence as an Excellent Prognostic Factor of Hepatocellular Carcinoma After Locoregional Therapy: A 5-Year Prospective Cohort Study.Front Oncol. 2021; 11: 756363. 29. Zhang X, Tsauo J, Tie J, Xue H, Zhao JB, Li JJ, Fang ZT, Guo WH, Li X. Emergent Transjugular Intrahepatic Portosystemic Shunt Creation for Acute Gastric Variceal Bleeding in Patients with Hepatocellular Carcinoma. J Vasc Interv Radiol. 2022,33(6):702-706. 30. Wang Q, Qiao W, Zhang H, Liu B, Li J, Zang C, Mei T, Zheng J, Zhang Y. Nomogram established on account of Lasso-Cox regression for predicting recurrence in patients with early-stage hepatocellular carcinoma. Front Immunol. 2022, 13:1019638. 31. Qiao W, Wang Q, Hu C, Zhang Y, Li J, Sun Y, Yuan C, Wang W, Liu B, Zhang Y. Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy. Front Immunol. 2022, 13:1019772. 32. Wang Q, Qiao W, Liu B, Li J, Yuan C, Long J, Hu C, Zang C, Zheng J, Zhang Y. The monocyte to lymphocyte ratio not only at baseline but also at relapse predicts poor outcomes in patients with hepatocellular carcinoma receiving locoregional therapy. BMC Gastroenterol. 2022, 22(1):98. 33. Wang Q, Guo D, Gao W, Yuan C, Li J, Zhang Y, He N, Zhao P, Zheng J, Zhang Y. Individual surveillance by competing risk model for patients with hepatocellular carcinoma occurrence in all-cause cirrhosis. J Cancer Res Clin Oncol. 2023, 149(14):13403-13416. 34. Sun Y, Qiao W, Wang Q, Liu B, Li J, Zhang H, Wang Q, Zhang Y, Wang W. Prognostic significance of globulin/low-density lipoprotein ratio in patients with hepatocellular carcinoma after local ablative therapy: a retrospective cohort study. Transl Cancer Res. 2023, 12(10):2533-2544. 35. Guo D, Li J, Zhao P, Mei T, Li K, Zhang Y. The hepatocellular carcinoma risk in patients with HBV-related cirrhosis: a competing risk nomogram based on a 4-year retrospective cohort study. Front Oncol. 2024, 14:1398968. 36. Huang Z, Li J, Mao N, et al. DBEF-Net: Diffusion-Based Boundary-Enhanced Fusion Network for medical image segmentation. Expert Systems with Applications.2024. 37. Qiao W, Li J, Wang P, Zhang Y, Jin R, Li J*. Prognostic nomogram based on the gamma-glutamyl transpeptidase-to-platelet ratio for patients with compensated cirrhotic hepatocellular carcinoma after local ablation. Front Oncol.2024, 14:1406764. 38. Jing C, Li J, Yuan C, Hu C, Ma L, Zheng J, Zhang Y. Therapeutic analysis of 632 cases treated by transcatheter arterial chemoembolization combined with ablation in hepatocellular carcinoma: A retrospective study. Eur J Radiol, 2024, 178:111619. 39. Xu X, Jing C, Zhu T, Jiang M, Fu Y, Li J*, Meng Q. Case report: POEMS syndrome with portal hypertension. Front Med, 2024 40. 靖长友,朱桐,张永宏,李建军*.经肝动脉化疗栓塞联合射频消融治疗早期肝癌的效果.肝脏,2024,29(7):1-4. 41. Zhenyang Huang, Jianjun Li, Ning Mao, Jinjiang Li. BADM: Boundary-Assisted Diffusion Model for Skin Lesion Segmentation. Eng Appl Artif Intell. 2024,137, Part B,109213. 42. Xu XT, Jiang MJ, Fu YL, Xie F, Li JJ*, Meng QH. Gut microbiome composition in patients with liver cirrhosis with and without hepatic encephalopathy: A systematic review and meta-analysis. World J Hepatol 2025; 17(1): 0-0. 论著： 1. 参编：《影像引导肿瘤消融治疗学》，人民卫生出版社，2013 2. 参编：《CT引导肝肿瘤消融治疗学》，人民卫生出版社，2011 3. 参编：《肿瘤介入治疗手册》，人民卫生出版社，2008